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Abstract: Objective: The aim of this study was to investigate the effect of combined intake of a high 
dose of aspirin, atorvastatin, captopril and metformin on oxidative stress in the brain cortex and 
hippocampus of streptozotocin (STZ)-induced diabetic rats. Material and methods: Rats were 
randomly divided into the following 11 groups: control and diabetic (D), as well as 9 groups that 
were treated with metformin (M, 300 mg/kg) or aspirin (ASA, 120 mg/kg) alone or in different 
combinations with captopril (C, 50 mg/kg) and/or atorvastatin (AT, 40 mg/kg) as follows: (D + M), 
(D + ASA), (D + M + ASA), (D + M + C), (D + M + AT), (D + M + C + ASA), (D + M + C + AT), (D + M 
+ AT + ASA) and (D + M + C + AT + ASA). The rats in treatment groups received drugs by gavage 
daily for six weeks. Serum lipid profile and levels of oxidative markers in the brain cortex and 
hippocampus tissues were evaluated. Results: The levels of malondialdehyde in the brain cortex 
and hippocampus in all the treated groups decreased significantly (p < 0.05). There was a significant 
increase in the total thiol concentration as well as catalase activity in treated rats in (M + AT), (M + 
C + ASA), (M + C + AT), (M + AT + ASA) and (M + C + AT + ASA) groups in cortex and hippocampus 
in comparison with the diabetic rats (p < 0.05). Also, the superoxide dismutase activity in all treated 
rats with medications was significantly increased compared to the diabetic rats (p < 0.05–0.01). 
Conclusion: Our findings showed that the combined use of high-dose aspirin, metformin, captopril 
and atorvastatin potentiated their antioxidant effects on the brain, and hence could potentially 
improve cognitive function with their neuroprotective effects on hippocampus. 
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1. Introduction 
Diabetes mellitus (DM) is a metabolic disease with multi-organ involvement including kidney, 
heart and even the brain [1,2]. There is growing evidence that oxidative stress is a possible mechanism 
in the development of diabetes-related complications. It has been shown that glucose autoxidation 
along with activated polymorphonuclear cells in diabetes results in oxidative stress via hydroxyl and 
superoxide radicals generation [3]. 
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Metformin, atorvastatin, aspirin and captopril are the frequently used medications in people 
with diabetes. The role of these medications on oxidant–antioxidant balance in diabetes is crucial. In 
this study, we investigated the role of these medications on the redox system. 
Metformin is the first line anti-hyperglycemic agent used in the management of patients with 
type 2 diabetes [4]. Metformin reduces intracellular reactive oxygen species (ROS) levels by 
potentiating the activity of the antioxidant enzymes [5]. 
Dyslipidemia is commonly associated with DM [6], and statins are the most commonly used 
medications to treat this. Statins (e.g., atorvastatin) are lipid-lowering drugs [7], which reduce the 
risk of cardiovascular complications. Also, statins have multiple pleiotropic effects [8–12] including 
antioxidant activity via inhibition of NAD(P)H oxidase and free radical scavenging activity [13–15]. 
Aspirin (ASA) is another drug that is commonly used for secondary prevention of 
cardiovascular events in patients with diabetes [16]. Aspirin acts as an anti-oxidant by reducing the 
generation of multiple free radicals such as superoxide and by preventing reduction of antioxidant 
enzymes activity such as catalase and superoxide dismutase [17]. 
In addition, captopril, an Angiotensin II (Ang II) converting enzyme (ACE) inhibitor, is 
commonly used for secondary prevention of cardiovascular events in patients with diabetes. It can 
selectively lower the Ang II, endothelin and oxidative stress, which may have a potential role in its 
blood pressure-lowering effect [18]. 
There is some evidence to show that there is an increased risk of development of diabetes 
associated with statin use, and there is a renewed interest to find novel therapeutic approaches for 
managing hyperlipidemia. In addition, there is some evidence to show that high dose of aspirin may 
potentially have a role in lipid metabolism. Also a high dose of aspirin, unlike statin, can potentially 
ameliorate insulin resistance and improve glucose tolerance in patients with type 2 diabetes [19]. In 
view of this, there are ongoing studies on the use of high dose of aspirin in patients with diabetes. On 
the other hand, the effects of combinations of drugs on human health have recently become important 
since many patients take multiple medications simultaneously [20]. Since there has been no study on 
the effect of combined administration of atorvastatin, captopril, metformin and a high dose of aspirin 
on oxidative stress in the brain tissue, we studied this effect in a streptozotocin (STZ)-induced diabetic 
model. 
2. Materials and Methods 
2.1. Chemicals and Drugs 
All drugs were purchased from Sigma (Darmstadt, Germany). Aspirin, CAS No. 50-78-2; 
atorvastatin, CAS No. 134523-00-5; metformin, CAS No. 657-24-9; captopril, CAS No. 62571-86-2; and 
streptozotocine, CAS No. 55325-01-4. 
2.2. Streptozotocin-Induced Diabetes 
For diabetes induction, a single dose of streptozotocin (60 mg/kg) was dissolved in distilled 
water and injected intraperitoneally (i.p.). Three days after the STZ injection, we evaluated fasting 
glucose levels in blood samples provided from the tail vein using a glucometer to certify the induction 
of diabetes. Rats with blood glucose level of ≥250 mg/dL were classified as diabetic[21]. 
2.3. Animals 
Healthy adult male Wistar rats (250–280 g, 10 weeks old) were housed under standard 
conditions with 12-h light–dark cycle at a temperature 22 ± 2 °C with free access to food and water. 
All tests were carried out under license from the Animal Experimentation Ethics Committee of the 
Mashhad University of Medical Sciences (approval code: IR.MUMS.FM.REC. 1395.200, approval 
date: 20 July 2016). 
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2.4. Experimental Groups 
Rats were randomly divided into the following 11 groups (8 animals in each group): control and 
diabetic (D), as well as 9 groups that were treated with metformin (M, 300 mg/kg) or aspirin (ASA, 
120 mg/kg) alone or in different combinations with captopril (C, 50 mg/kg) and/or atorvastatin (AT, 
40 mg/kg) as follows: (D + M), (D + ASA), (D + M + ASA), (D + M + C), (D + M + AT), (D + M + C + 
ASA), (D + M + C + AT), (D + M + AT + ASA) and (D + M + C + AT + ASA). The rats in treatment 
groups received daily drugs by gavage for 6 weeks. Serum lipid profile and levels of oxidative stress 
markers in the brain cortex and the hippocampus tissues were evaluated. All drugs were dissolved 
in saline. 
2.5. Measurement of Total Thiol 
The total thiol was determined in line with the methods of Sedlak and Lindsay [22]. The gastric 
and liver tissues of control and treated rats were removed and homogenised in ice-cold water and 
then were centrifuged. The supernatant (50 μL) was added to 1 mL Tris-EDTA 
(ethylenediaminetetraacetic acid) buffer (pH 8.6) and the absorbance was read at 412 nm against Tris-
EDTA buffer alone (A1). Then, 20 μL of 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB; 10 mM in 
methanol) was mixed with the supernatant and the absorbance was read again (A2). The absorbance 
of DTNB reagent was also read as blank (B). The total thiol was expressed as mmol/g tissue. 
2.6. Measurement of Malondialdehyde 
Malondialdehyde (MDA) was measured using thiobarbituric acid (TBA) as described by Mihara 
et al. [23]. One millilitre of the supernatant of the homogenised gastric and liver tissues was added to 
2 mL of a complex solution containing TBA, trichloroacetic acid (TCA) and hydrochloric acid (HCl). 
This was then boiled in a water bath for 40 min. After reaching room temperature, the solution was 
centrifuged at 1000 g for 10 min. The absorbance was read at 535 nm. The MDA levels were expressed 
as μmol/g tissue. 
2.7. Determination of Superoxide Dismutase (SOD) Activity 
SOD activity was assayed by Madesh and Balasubramanian method. A colorimetric assay 
involving superoxide production by pyrogallol auto-oxidation and the inhibition of superoxide-
dependent reduction of the tetrazolium dye, MTT (3-(4, 5-dimethylthiazol-2-yl) 2, 5-
diphenyltetrazolium bromide) to its Formazan by SOD was evaluated at 570 nm. The quantity of 
enzyme causing 50% inhibition in the MTT decline rate was determined as one unit of SOD activity 
[24]. 
2.8. Measurement of Catalase Activity 
Catalase activity was determined by applying the procedure described by Zini et al. by reducing 
the concentration of H2O2 when incubated with the test samples. The quantity of tissue capable to 
decline the amounts of H2O2 existing in solution by 50% was determined as one unit of catalase-like 
activity [25]. 
2.9. Lipid Profile Assessment 
Serum cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density 
lipoprotein cholesterol (HDL-C) were measured on day 0 and 45 using Pars Azmoon kits (Karaj, Iran). 
2.10. Data Analysis 
The results were expressed as mean ± standard error of the mean (SEM). Statistical analysis was 
performed by one-way ANOVA followed by the Tukey test. p < 0.05 was considered significant. 
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3. Results 
Serum glucose concentration in the diabetic group and all groups treated with metformin and 
aspirin alone or different combinations of metformin, aspirin, atorvastatin and captopril were 
significantly higher than the control group. On day 45, this amount in all drug-treated groups was 
significantly lower than diabetic group (p < 0.05 to 0.01) (Figure 1). 
 
Figure 1. Glucose levels on days 0, 3 and 45 of the experimental period. Data are shown as mean ± 
standard error of the mean (SEM). * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to control. + p < 
0.05 and ++ p < 0.01 compared to diabetic group. D, diabetic; M, metformin; ASA, aspirin; AT, 
atrovastatin; and C, captopril. 
On day 45, serum total cholesterol concentration in the diabetic group was significantly higher 
compared to the control group (p < 0.001). All drug-treated groups, except the aspirin-only-treated 
group, showed a significant reduction in serum cholesterol concentration compared to the diabetic 
group (p < 0.05 to p < 0.01). Groups which received combinations of three or four drugs showed a 
significant reduction in serum cholesterol compared to groups received one or two drugs (p < 0.05 to 
p < 0.01). Among the three groups that received combinations of two drugs, a significant decline in 
serum cholesterol concentration was observed in (D + M + ASA) and (D + M + AT) groups, compared 
to the (D + ASA) group (Figure 2A). 
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Figure 2. Serum levels of cholesterol (A), triglyceride (B), LDL-cholesterol (C) and HDL-cholesterol 
(D). Data are shown as mean ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to control group, 
and + p < 0.05, ++ p < 0.01 and +++ p < 0.001 compared to diabetic group. D, diabetic; M, metformin; 
ASA, aspirin; AT, atrovastatin and C: captopril. 
There was a significant increase in serum triglyceride concentration in the diabetic group 
compared to the control group on day 45 (p < 0.001). Serum triglyceride concentration in groups 
which received combinations of three or four drugs was significantly lower than the diabetic group 
(p < 0.01 to 0.001). Among the three groups treated with combinations of two drugs, only the (D + M 
+ AT) group showed a significant reduction in serum triglyceride concentration compared to the 
diabetic group (p < 0.001). Also, triglyceride concentration in groups that received combinations of 
three or four drugs was significantly reduced as compared to groups treated with one drug or 
combinations of two drugs (Figure 2B). 
On day 45, serum LDL concentration was significantly higher in the diabetic group compared 
to the control group (p < 0.001). All drug-treated groups, except the ASA group, showed significant 
decreases in serum LDL concentration compared to the diabetic group (p < 0.05 to 0.01). LDL 
concentration in all groups treated with different combinations of drugs were significantly lower 
compared to ASA group (p < 0.05) (Figure 2C). 
In the diabetic group, serum HDL concentration on day 45 was significantly lower than those of 
the control group (p < 0.01). All drug-treated groups, except the ASA group, showed a significant 
increase in serum HDL concentration compared to the diabetic group (p < 0.05 to 0.01). HDL 
concentration indicated significant increases in the groups which received a combination of four 
drugs compared to the ASA group (p < 0.05) (Figure 2D). 
Malondialdehyde level was increased in the cortex (p < 0.05) and hippocampus (p < 0.01) tissues 
in the diabetic group compared to the control group. Administration of captopril, aspirin, 
atorvastatin, metformin and their combinations reduced MDA level significantly compared to the 
diabetic group (p < 0.05) (Figure 3A,B). 
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The total thiol concentration in cortex and hippocampus in rats treated with (M + AT), (M + C + 
ASA), (M + C + AT), (M + AT + ASA) and (M + C + AT + ASA) significantly increased in comparison 
with the diabetic rats (p < 0.05) (Figure 3C,D). 
 
 
Figure 3. Malondialdehyde (MDA) and total thiol concentrations in the cortex (A,C) and 
hippocampus (B,D) tissues. Data are shown as mean ± SEM. * p < 0.05 and ** p < 0.01 compared to 
control. + p < 0.05 compared to non-treated diabetic group. D, diabetic; M, metformin; ASA; aspirin; 
AT, atorvastatin; and C, captopril. 
Also, the SOD activity in diabetic rats significantly decreased compared to the control group (p 
< 0.01). Superoxide dismutase activity boosted significantly in all groups treated with captopril, 
aspirin, atorvastatin, metformin and their combinations compared to the diabetic rats (p < 0.05 to p < 
0.01) (Figure 4). 
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Figure 4. Superoxide dismutase (SOD) activity in the brain cortex (A) and hippocampus (B) tissues. 
Data are shown as mean ± SEM. ** p < 0.01 compared to control group, + p < 0.05 and ++ p < 0.01 
compared to diabetic group. D, diabetic; M, metformin; ASA, aspirin; AT, atorvastatin; and C, 
captopril. 
Finally, the catalase activity in brain cortex (p < 0.05) and hippocampus (p < 0.01) in diabetic rats 
significantly decreased compared to the control group. All groups treated with captopril, aspirin, 
atorvastatin, metformin and their combinations potentiated catalase activity compared to the diabetic 
group, but this increase was significant only in (M + AT), (M + C + ASA), (M + C + AT), (M + AT + 
ASA) and (M + C + AT +ASA) groups (p < 0.05) (Figure 5). 
 
Figure 5. The catalase activity in the brain cortex (A) and hippocampus (B) tissues. Data were shown 
as mean ± SEM. * p < 0.05 and ** p < 0.01 compared to control and + p < 0.05 compared to diabetic 
group. D, diabetic; M, metformin; ASA, aspirin; AT, atorvastatin; and C, captopril. 
4. Discussion 
This study shows that the combined administration of all considered drugs produced more 
beneficial effects on glucose levels compared to the administration of individual drugs. In groups 
treated with metformin (D + M) or groups that received combinations of metformin and captopril (D 
+ M + C), atorvastatin (D + M + AT) or aspirin (D + M + ASA), the total cholesterol, LDL-cholesterol 
and HDL-cholesterol levels significantly improved in contrast to the (D + ASA) group. This suggests 
that aspirin alone has no positive effect on lipid profile improvement. However, some recent studies 
reported that high-dose aspirin influences lipid metabolism [26,27]. 
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In the present study, metformin improved the lipid profile when administered alone or in 
combination with captopril. Previous studies have demonstrated that metformin, as an anti-
hyperglycaemic drug [28,29], and captopril can improve glucose and lipid metabolism [30]. In 
addition, the combination of metformin and atorvastatin (D + M + AT) reduced total cholesterol and 
LDL-cholesterol to a greater extent compared to the combination of metformin and aspirin (D + M + 
ASA) or captopril (D + M + C). Combination of metformin and atorvastatin (D + M + AT) significantly 
reduced TG in comparison with groups that received the combination of metformin and captopril 
and aspirin (D + M + C + ASA). Comparison of the groups that received combinations of three drugs 
demonstrated that in groups where atorvastatin was present (i.e., D + M + C + AT and D + M + ASA 
+ AT groups), there was a significant decrease in TG levels compared to the treatment regimens that 
did not include atorvastatin (i.e., D + M + C + ASA group) suggesting high efficacy of atorvastatin in 
improving lipid profiles similar to previous studies [31]. 
Oxygen–glucose deprivation (OGD) in neurons increases extracellular glutamate levels leading 
to toxicity. Glutamate uptake from the synaptic space by glutamate transporters is altered by 
oxidative stress. Oxidative stress is associated with decreased activity of glutamate transporters as 
well as glutamine synthase, thereby increasing extracellular glutamate concentrations that may 
aggravate damage to neurons [32]. 
The possible mechanisms by which oxidative damage is involved in the pathophysiology of 
diabetes include activation of transcription factors, protein kinase C and advanced glycated end 
products (AGEs) [33]. Enhancement of nitric oxide (NO) generation in the brain in diabetes state 
induces nitrosative damage as well oxidative stress and the combination of NO with ROS resulting 
in the formation of a very toxic complex of peroxynitrite (ONOO-) that yields to the protein 
nitrotyrosination and cell death [34]. 
Studies have demonstrated the neuroprotective effect of angiotensin receptor blockers [35]. Mogi 
et al. demonstrated the preventive effects of telmisartan, a specific AT1 inhibitor, on cognitive and 
memory impairment in mice with Alzheimer disease induced by diabetes. Therefore, RAS inhibition 
by AT1 receptor antagonists or ACE inhibitors that are commonly used as anti-hypertensive drugs 
will be potentially able to prevent neurodegenerative diseases [36]. 
Abbasi et al. have been indicated that inhibition of RAS by using special inhibitors, valsartan 
(specific AT1 inhibitor) and captopril (ACE inhibitor), potentiates the antioxidant defense system of 
the brain. There was decreased oxidative/nitrosative stress as well as improvement of memory and 
cognitive function in neuronal damage during AD in diabetic rats. In this study, treatment with 
captopril as well as valsartan increased SOD and catalase activities [37]. This suggests that captopril 
has an antioxidant effect on the brain and hippocampus in diabetic rats. Therefore, the reduction of 
oxidative stress in the hippocampus can potentially lead to the improvement of memory and 
cognitive function. Enhancement in oxidative damage markers may be due to the increased Ang II 
formation and ACE activity, which stimulates NADPH oxidase, the key enzyme in the production of 
ROS, and plays a crucial role in the progression of oxidative stress [37]. 
Previous studies have been shown that the treatment of diabetes with metformin significantly 
increased the antioxidant enzymes’ activities and generally potentiated the antioxidant defense 
system in these cases [38,39]. Metformin prevents the oxidative stress consequences on apoptosis and 
inhibits the mitochondria-related toxicity of hyperglycaemia. In addition, the oxidative stress in 
endothelial cells was completely prevented by metformin. Treatment with metformin significantly 
increased glutathione levels. This finding reinforces the idea that the antidiabetic agent, metformin, 
has an important antioxidant function in the nervous system [40]. Therefore, this study demonstrated 
the antioxidant effects of metformin on the brain as well as its anti-hyperglycemic effects. 
Aspirin, an NSAID with neuroprotective effects, inhibits brain iNOS expression as well as 
oxidative damage and ATP loss induced by immobilisation stress [41]. Castilli et al. have shown that 
low doses of aspirin has direct neuroprotective effects in patients with cerebral ischemia [42]. Also 
Moro et al. have demonstrated that ASA has potential neuroprotective effects by various mechanisms 
including inhibition of NF-kB translocation to the nucleus, interference with the mechanism leading 
to IkB phosphorylation and inhibition of oxidative stress [43]. Oxidative stress may activate the 
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cytoplasmic NF-kB leading to its translocation to the nucleus [44]. Furthermore, inhibition of NF-kB 
activation by ASA has neuroprotective actions against neurotoxicity induced by glutamate [45]. 
Atorvastatin, a cholesterol-lowering drug, also has neuroprotective effects. Neuroprotective 
effects of statins such as atorvastatin may confer significant clinical benefit [46,47]. Studies have 
suggested that the putative anti-inflammatory and antioxidant properties of statins may confer 
additional neuroprotection in patients with cerebral ischaemia [48]. As a result, atorvastatin-induced 
neuroprotection may be associated with the reduction of oxidative stress. It inhibited OGD 
production as well as ROS. The addition of cholesterol before OGD and reoxygenation abolished the 
neuroprotective effect of atorvastatin as well as on glutamine synthetase and glutamate uptake 
activity. Furthermore, atorvastatin is capable of preventing cell death induced by OGD via 
amelioration of glutamine synthetase and glutamate uptake activity and reduces oxidative stress. 
Moreover, the effects of atorvastatin were related to its function on cholesterol synthesis inhibition. 
Indeed, atorvastatin could be a useful agent in the prevention of glutamate toxicity involved in brain 
damages such as vascular diseases [32]. The studies have been shown that increased oxidative stress 
in the parietal lobe of the cerebral cortex was related to poorer learning. Therefore, novel 
pharmacological effects of atorvastatin mediated by decreasing oxidative stress may be an important 
mechanism underlying the benefits of this agent. Generally, statins such as atorvastatin with higher 
blood–brain barrier penetrance have antioxidant effects and beneficial effects on cognition [49]. There 
are several neuroprotective pathways that could be affected by statins including BDNF production 
and activation of the PKB/Akt, Wnt and ERK pathways. Increased BDNF levels may activate PI3-
kinase, which in turn activates PKB/Akt. PKB/Akt phosphorylates GSK-3β, thus reducing inhibition 
of the Wnt-signalling pathway. Also, statins can activate PKB/Akt by inhibiting PTEN (through Rho 
and Rho kinase) [50–52]. 
Our results demonstrated a significant increase of catalase and SOD activity in all groups and 
total thiol concentration in most groups that received different combinations of aspirin, atorvastatin, 
metformin and captopril. These results are in line with some previous studies that showed a 
combination of drugs exhibits additive effects on the reduction of oxidative stress. For example, Koh 
et al. and Qin et al. illustrated that a combination of statins with the inhibitors of the angiotensin II 
system exhibited a more potent reducing effect on oxidative stress [53,54]. Also, Giorgia et al. 
investigated putative additive effects of aspirin and statins in diabetes. Their study provided 
important information regarding the preventive role of aspirin in diabetes when used with statins to 
control cardiovascular risk factors [55]. Our findings showed that the combination of aspirin with 
atorvastatin, metformin and captopril, which are commonly consumed by patients with diabetes, 
potentiated the antioxidant effects of these medications and reduced oxidative stress. Further 
investigations are warranted to investigate the impact of emerging drug classes [56,57,58] and their 
combination with conventionala gents on oxidative stress and other aspects of neurological function 
in diabetic patients as well as other patient groups at a high risk of cardiovascular disease. 
5. Conclusions 
This study showed that combined use of atorvastatin, metformin, captopril and aspirin in 
diabetic rats potentiate their antioxidant effects on the brain and maybe have a beneficial effect on 
the cognitive functions possibly by neuroprotective effects on hippocampus area. 
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